Robert Heimer1, Weihai Zhan2, Lauretta E Grau2. 1. Center for Interdisciplinary Research on AIDS and the Department of Epidemiology of Microbial Disease, Yale University School of Public Health, 60 College Street, New Haven, CT 06520, United States. Electronic address: robert.heimer@yale.edu. 2. Center for Interdisciplinary Research on AIDS and the Department of Epidemiology of Microbial Disease, Yale University School of Public Health, 60 College Street, New Haven, CT 06520, United States.
Abstract
AIMS: To explore the relationship between chronic pain and characteristics, behaviors, and psychological status of suburban Connecticut injection drug users. METHODS: Cross-sectional study with quantitative interview and serological testing for HIV and hepatitis B and C in 456 individuals who injected drugs in the past month. Participants were dichotomized into those reporting current chronic pain of at least six months duration and all others. The interview covered (i) sociodemographics, (ii) injection drug use, (iii) interactions with drug treatment, criminal justice, and harm reduction, (iv) screening for alcohol use, chronic pain, anxiety, and depression, and (v) knowledge regarding HIV, hepatitis B (HBV) and C (HCV), and opioid overdose. Serological testing for HIV, HBV, and HCV was conducted. RESULTS: One-third (n = 143) reported chronic pain. These individuals differed significantly from those not reporting chronic pain on characteristics that included older age, lower educational achievement, and injection of pharmaceutical opioids. They also reported experiencing more psychological and family problems on the ASI and higher levels of depression and anxiety. Four of five individuals with chronic pain (n = 117) reported non-medical opioid use prior to the onset of chronic pain. CONCLUSIONS: Chronic pain is common among drug injectors in our study population although it was unusual for chronic pain to have preceded non-medical opioid use. Psychological problems in injectors with co-occurring chronic pain are likely pose significant complications to successful treatment for substance abuse, pain, or infectious disease treatment.
AIMS: To explore the relationship between chronic pain and characteristics, behaviors, and psychological status of suburban Connecticut injection drug users. METHODS: Cross-sectional study with quantitative interview and serological testing for HIV and hepatitis B and C in 456 individuals who injected drugs in the past month. Participants were dichotomized into those reporting current chronic pain of at least six months duration and all others. The interview covered (i) sociodemographics, (ii) injection drug use, (iii) interactions with drug treatment, criminal justice, and harm reduction, (iv) screening for alcohol use, chronic pain, anxiety, and depression, and (v) knowledge regarding HIV, hepatitis B (HBV) and C (HCV), and opioid overdose. Serological testing for HIV, HBV, and HCV was conducted. RESULTS: One-third (n = 143) reported chronic pain. These individuals differed significantly from those not reporting chronic pain on characteristics that included older age, lower educational achievement, and injection of pharmaceutical opioids. They also reported experiencing more psychological and family problems on the ASI and higher levels of depression and anxiety. Four of five individuals with chronic pain (n = 117) reported non-medical opioid use prior to the onset of chronic pain. CONCLUSIONS:Chronic pain is common among drug injectors in our study population although it was unusual for chronic pain to have preceded non-medical opioid use. Psychological problems in injectors with co-occurring chronic pain are likely pose significant complications to successful treatment for substance abuse, pain, or infectious disease treatment.
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: Andrew Rosenblum; Herman Joseph; Chunki Fong; Steven Kipnis; Charles Cleland; Russell K Portenoy Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: John C Landefeld; Christine Miaskowski; Lina Tieu; Claudia Ponath; Christopher T Lee; David Guzman; Margot Kushel Journal: J Pain Date: 2017-04-12 Impact factor: 5.820
Authors: Chia Li; Jonathan A Sugam; Emily G Lowery-Gionta; Zoe A McElligott; Nora M McCall; Alberto J Lopez; Jessica M McKlveen; Kristen E Pleil; Thomas L Kash Journal: Neuropsychopharmacology Date: 2016-01-21 Impact factor: 7.853
Authors: Rachel Carmen Ceasar; Alex H Kral; Kelsey Simpson; Lynn Wenger; Jesse L Goldshear; Ricky N Bluthenthal Journal: Drug Alcohol Depend Date: 2020-11-23 Impact factor: 4.492